Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 20 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; lactose monohydrate; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; croscarmellose sodium; colloidal anhydrous silica; lactose monohydrate; hyprolose; magnesium stearate; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 20 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; hyprolose; colloidal anhydrous silica; croscarmellose sodium; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - dasatinib, quantity: 70 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate; titanium dioxide; hypromellose; triacetin - dasatinib sun is indicated for the treatment of adults aged 18 years or over with:,? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase.,? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib.,? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy.,? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib sun is indicated for the treatment of paediatric patients with:,? ph+ cml in the chronic phase.,? newly diagnosed ph+ all in combination with chemotherapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - esomeprazole sodium, quantity: 42.6 mg (equivalent: esomeprazole, qty 40 mg) - injection, powder for - excipient ingredients: disodium edetate; sodium hydroxide - ? the short-term management of gastro-oesophageal reflux disease (gord) in patients with oesophagitis and/or severe symptoms of reflux as an alternative when oral therapy is inappropriate. ? prevention of rebleeding in patients following therapeutic endoscopy for acute, bleeding gastric or duodenal ulcers. ? short-term management in patients requiring continued non-steroidal anti- inflammatory drug (nsaid) therapy when oral therapy is inappropriate: ? healing of gastric ulcers associated with nsaid therapy ? prevention of gastric and duodenal ulcers associated with nsaid therapy, in patients at risk ? esomeprazole sun should be replaced with oral therapy as soon as practicable.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: hydrochloric acid; sodium hydroxide; sucrose; histidine; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; hydrogenated soy phosphatidylcholine; ammonium sulfate; ethanol; water for injections - liposomal doxorubicin sun, as monotherapy, is indicated for the treatment of metastatic breast cancer.,liposomal doxorubicin sun is also indicated for the treatment of:,? advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.,? aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.,liposomal doxorubicin sun may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline).,liposomal doxorubicin sun is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: water for injections; cholesterol; ethanol; hydrogenated soy phosphatidylcholine; ammonium sulfate; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; histidine; hydrochloric acid; sodium hydroxide; sucrose - liposomal doxorubicin sun, as monotherapy, is indicated for the treatment of metastatic breast cancer.,liposomal doxorubicin sun is also indicated for the treatment of:,? advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.,? aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease.,liposomal doxorubicin sun may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). liposomal doxorubicin sun is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pemetrexed disodium, quantity: 1102.8 mg (equivalent: pemetrexed, qty 1000 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pemetrexed disodium, quantity: 551.4 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pemetrexed disodium, quantity: 110.28 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.